note short lot new
write thing go great best thing compani keep
repeat great result deliv put stellar
quarter probabl best-ev across board beat consensu revenu
use strong sale drive meaning profit well consensu
preview expect anoth beat frankli think anyon expect
beat volum growth easili surpass price pressur move
pharmaci and/or competit dynam expect continu
time seem clear us cgm becom standard care type diabet
adopt benefit dynam surpris see
share slide afterhour exactli sure investor may
want result meet expect remain neutral given concern
price may get wors point market could slow around time
frankli stellar quarter increas bia toward share
continu well surpris share ralli hour
guidanc move materi higher revenu expect
vs previou om expect
vs previou given dxcm track record model top end
guidanc rang
would call blip anyth would harp
issu quarter manag mention
continu run capac issu fulli resolv later
year manag would prefer thu expect
doubl capac end year ou sale flat manag
said time distributor order seem
reason alarm ou growth continu go forward
valuat rate neutral risk discuss
idc btig estim compani document
million except per share amount
believ time cgm primari method monitor glucos insulin-depend
commentari competit emphas posit impact term referr volum potenti new
patient feel new competit also put pressur price next year take user
concern competit price like immedi and/or increas spend expect meet
revenu estim wonder happen price throughout year
competit announc launch
continu robust adopt
acceler adopt
faster shift toward pharmaci channel greater volum uplift far outweigh
continu stabil possibl favor price environ
slowdown adopt
visibl impact cgm competit
drop price due competit reimburs
dedic improv live
diabet cgm compani
went public
year commerci
sever iter
product becom market
leader share cgm
asid creat
system compani
entrench diabet
manag ecosystem stand
benefit innov
develop intern extern
high qualiti open
partnership research
hacker pump compani
far outstrip consensu expect top sale estim gross margin
bp lower project compani continu invest increas manufactur capac year
oper expens higher model spend compani report non-gaap ep
cent better forecast
revis model strong sale beat updat guidanc significantli increas forecast sensor
revenu tweak transmitt receiv sale reflect trend quarter increas outlook
patient volum well sensor kit order also increas sale estim year model
top end new revenu guidanc rang
incom statement tweak gross margin higher account guidanc higher revenu volum
forecast still gross margin forecast reduc bp lower gross margin
observ adjust opex reflect guidanc higher revenu level
model non-gaap ep prior prior
actualsbtig estimate variancetot revenu net incom spend spend opex spend btig estim compani filingsvari
rate neutral believ current multipl estim ntm ev/sal expens given
potenti price pressur face increas competit valuat seem support mani
investor risk rate includ competit increas spend chang revenu growth rate fda product
recal reimburs price pressur
exhibit comp tabl large-cap peer
bpsebit bp btig estim compani filingsnewold changentm inc ingnnot sciencesexasbuy medicalwmginot factset data btig estimatespr ptpricemarket cap bev/salescagrev/gross profit
incom product develop grant oper expens tax expens net incom share net incom net incom analysisgross profit net incom revenu oper oper btig estim compani report
revenu eworldwid patient basebegin new drop patient re-ord disclos histor patient price revenu re-ord disclos histor patient price revenu hardwar revenu sensor kit order per quarter disclos histor per sensor revenu product btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
